NYSE: KVUE
Kenvue
Consumer Staples · Perfumes, Cosmetics & Other Toilet Preparations
52-week range
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.$34.2B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2021, ended Jan 2, 2022 | — |
| FY2022, ended Jan 1, 2023 | — |
| FY2023, ended Dec 31, 2023 | $41.2B |
| FY2024, ended Dec 29, 2024 | $41.1B |
| FY2025, ended Dec 28, 2025 | $32.9B |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | $34.2B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.$15.5B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2021, ended Jan 2, 2022 | $15.1B |
| FY2022, ended Jan 1, 2023 | $14.9B |
| FY2023, ended Dec 31, 2023 | $15.4B |
| FY2024, ended Dec 29, 2024 | $15.5B |
| FY2025, ended Dec 28, 2025 | $15.1B |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | $15.5B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2021, ended Jan 2, 2022 | $2.08B | $39.0M |
| FY2022, ended Jan 1, 2023 | $2.06B | $2.15B |
| FY2023, ended Dec 31, 2023 | $1.66B | $2.70B |
| FY2024, ended Dec 29, 2024 | $1.03B | $1.33B |
| FY2025, ended Dec 28, 2025 | $1.47B | $1.72B |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | $1.69B | $2.34B |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.$1.04B
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2021, ended Jan 2, 2022 | $740M |
| FY2022, ended Jan 1, 2023 | $1.23B |
| FY2023, ended Dec 31, 2023 | $1.38B |
| FY2024, ended Dec 29, 2024 | $1.07B |
| FY2025, ended Dec 28, 2025 | $1.06B |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | $1.04B |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.$8.21B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2021, ended Jan 2, 2022 | — |
| FY2022, ended Jan 1, 2023 | $0 |
| FY2023, ended Dec 31, 2023 | $8.29B |
| FY2024, ended Dec 29, 2024 | $8.61B |
| FY2025, ended Dec 28, 2025 | $8.52B |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | $8.21B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Up 12.0% since 2021.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.1.92B
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2021, ended Jan 2, 2022 | 1.72B |
| FY2022, ended Jan 1, 2023 | 1.91B |
| FY2023, ended Dec 31, 2023 | 1.91B |
| FY2024, ended Dec 29, 2024 | 1.91B |
| FY2025, ended Dec 28, 2025 | 1.92B |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | 1.92B |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Sep 27, 2026. Hover or tap a column for another year.Net: $120M more issued than bought back
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2021, ended Jan 2, 2022 | — | $141M |
| FY2022, ended Jan 1, 2023 | $0 | $137M |
| FY2023, ended Dec 31, 2023 | $7.00M | $188M |
| FY2024, ended Dec 29, 2024 | $235M | $254M |
| FY2025, ended Dec 28, 2025 | $197M | $136M |
| Trailing 12 months to Sep 27, 2026 (through Q3 FY2026) | $0 | $120M |
Revenue (TTM)
$15.5B
+3.5% YoY
Net income (TTM)
$1.69B
+17.9% YoY
Cash
$1.04B
−8.8% YoY
Total debt
$8.21B
−8.5% YoY
Valuation
At current price- Market Cap
- $37.1B
- P/E
- 22.0×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 2.4×
- Price / Book
- 3.7×
- EV / EBITDA
- 13.5×
Growth
Trailing 12 months- Revenue (TTM)
- $15.5B
- Revenue Growth YoY
- 3.5%
- Revenue CAGR 3Y
- 0.4%
- Revenue CAGR 5Y
- —. Compound annual growth over the last 5 fiscal years
- EPS Growth YoY
- 17.3%
- Net Income Growth YoY
- 17.9%
Profitability
Trailing 12 months- Gross Margin
- 58.3%
- Operating Margin
- 17.4%
- Net Margin
- 10.9%
- FCF Margin
- 15.1%
- Return on Equity
- 16.3%
Earnings
Trailing 12 months- Net Income
- $1.69B
- EPS (diluted)
- $0.88
- EBITDA
- $3.28B
- Operating Income
- $2.71B
Balance Sheet
As of Sep 27, 2026- Cash and cash equivalents
- $1.04B
- Total Debt
- $8.21B
- Net Debt
- $7.17B
- Total Assets
- $26.7B
- Total Liabilities
- $16.5B
- Shareholders' Equity
- $10.2B
Cash Flow
Trailing 12 months- Operating Cash Flow
- $2.73B
- Capital Expenditure
- $393M
- Free Cash Flow
- $2.34B
Dividends and risk
Last 12 months- Dividend Yield
- 5.4%
- Dividend / Share
- $1.04
- Beta (5Y)
- 0.48
Every ratio is calculated from the company’s reported figures.
Note
Revenue is roughly flat year over year at $15.5B.
Note
Net margin of 10.9% over the last 12 months.
Note
Net debt of $7.17B is 2.2× EBITDA.
Strength
Turns 15.1% of revenue into free cash flow.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-Q for the quarter ended Sep 27, 2026 · filed Oct 30, 2026
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2025 · 10-K49Some concerns
10-K for the fiscal year ended Dec 28, 2025
Filed Feb 20, 2026 · Read the filing on EDGAR
- Kimberly-Clark agreed to buy Kenvue for 0.14625 K-C shares plus $3.50 cash per share. Shareholders have approved, and closing is expected in the second half of 2026.
- Sales fell 2.1% to $15.1 billion as volumes dropped, but net income rose 42.7% to $1.47 billion because write-downs were much smaller than in 2024.
- US officials suggested Tylenol use in pregnancy may be linked to autism. The FDA began a label change and Texas sued, which may hurt Tylenol sales.
- Skin Health and Beauty profit fell 21.4%. Its estimated value is only about 10% above its book value, so a future goodwill write-down is possible.
Business momentum
Mixed
“Net sales were $15.1 billion and $15.5 billion for the fiscal twelve months ended December 28, 2025 and December 29, 2024, respectively, a decrease of $331 million, or 2.1%.”
Outlook
Cautious
“The foregoing actions may depress sales of acetaminophen and could result in an increased risk of future litigation containing similar claims.”
Financial stress
Low
“Based upon our history of generating positive cash flows, we believe our existing cash and cash generated from operations will be sufficient to service our current obligations for at least the next 12 months.”
Tone against the previous report
About the same
Red flags
- Medium
Major lawsuit
“the Attorney General of Texas sought to block the payment of Kenvue's regular quarterly dividend in November 2025 in a lawsuit against us and our subsidiary Kenvue Brands LLC regarding the safety of our products containing acetaminophen.”
- Minor
Other
“the estimated fair value of the Skin Health and Beauty reporting unit exceeded the carrying value by approximately 10%; therefore, no impairment charge was recorded”
- Minor
Major lawsuit
“Since the announcement of the Proposed Transaction, certain of our shareholders and K-C's shareholders have filed lawsuits against us, K-C, and/or the board of directors of both companies”
Positives
Profit rebounded sharply as write-downs shrank
“Impairment charges were $23 million and $578 million for the fiscal twelve months ended December 28, 2025 and December 29, 2024, respectively, a decrease of $555 million.”
Restructuring cost savings goal reached
“we have realized annualized pre-tax gross cost savings in excess of $350 million as of the end of fiscal year 2025.”
Operating cash flow up 24%
“Net cash flows from operating activities were $2.2 billion and $1.8 billion for the fiscal twelve months ended December 28, 2025 and December 29, 2024, respectively, an increase of $428 million.”
Concerns
Sales volumes fell in all three segments
“Organic sales (a non-GAAP financial measure as defined in "Segment Results—Organic Sales Change" below) decreased 2.2% driven by volume-related decreases of 2.3%”
Skin Health and Beauty profit dropped sharply
“The Skin Health and Beauty Segment adjusted operating income decreased by $130 million, or 21.4%, to $477 million”
Losing market share and distribution in US skin care
“primarily attributable to distribution losses, underperformance in e-commerce, and current fiscal year competitive pressures resulting in market share losses”
New risks since the previous report
Pending Kimberly-Clark takeover may be delayed, fail or disrupt the business
“Failure to consummate the Proposed Transaction, or a delay in the consummation of the Proposed Transaction, could negatively impact our business, results of operations, financial condition, and stock price.”
Government claims linking Tylenol use in pregnancy to autism, plus FDA label change
“The FDA also stated it initiated the process for a label change for acetaminophen and issued a notice to physicians.”
US tariffs adding about $130 million in yearly costs
“we estimate gross tariff exposure of approximately”
Possible goodwill write-down in Skin Health and Beauty
“further deterioration of market conditions or an inability to execute on our strategies could lead to an impairment charge of the goodwill associated with the Skin Health and Beauty reporting unit in the future.”
Merger agreement limits share buybacks, deals and other business choices
“The Merger Agreement restricts us from entering into certain corporate transactions and from taking other specified actions without the consent of K-C until the closing of the Proposed Transaction.”
Biggest risks named
- Kimberly-Clark merger failing, being delayed or disrupting the business
- Acetaminophen (Tylenol) safety claims, lawsuits and label changes
- Weak Skin Health and Beauty sales and possible goodwill write-down
- Competition and pressure from large retailers
- Tariffs and rising input costs
Artificial intelligence in this business: Mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | −3 | |
| Outlook | −2 | |
| Tone against the previous report | 0 | |
| Financial stress | 0 | |
| Red flags | −4.5 | |
| New risks | −2 | |
| Score | 49 | |
Written by AI (Claude Opus 5.5) from the report’s text. 17 of 17 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-Q | Oct 30, 2026 | Pro | |||
| 10-K | Feb 20, 2026 | 49 | Mixed | 1 medium2 minor | |
| 10-K | Feb 24, 2025 | 38 | Sharp deterioration | 1 medium | |
| 10-K | Mar 1, 2024 | 55 | Mixed | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q3 FY2026 (period ended Sep 27, 2026), filed Oct 30, 2026. View filings on SEC EDGAR